What is Roth Capital’s Estimate for CervoMed Q1 Earnings?

CervoMed Inc. (NASDAQ:CRVO) – Analysts at Roth Capital upped their Q1 2025 earnings estimates for CervoMed in a research report issued on Tuesday, December 10th. Roth Capital analyst B. Pachaiyappan now anticipates that the company will post earnings of ($0.52) per share for the quarter, up from their prior estimate of ($0.53). Roth Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for CervoMed’s current full-year earnings is ($1.76) per share. Roth Capital also issued estimates for CervoMed’s Q2 2025 earnings at ($0.44) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.27) EPS and FY2025 earnings at ($1.57) EPS.

Several other research firms have also weighed in on CRVO. Chardan Capital reiterated a “neutral” rating on shares of CervoMed in a research note on Wednesday. Canaccord Genuity Group lowered their price objective on shares of CervoMed from $65.00 to $12.00 and set a “buy” rating for the company in a research report on Wednesday. Morgan Stanley reissued an “underweight” rating on shares of CervoMed in a report on Wednesday. Brookline Capital Management lowered CervoMed from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 10th. Finally, D. Boral Capital reiterated a “hold” rating on shares of CervoMed in a research report on Tuesday, December 10th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, CervoMed currently has a consensus rating of “Moderate Buy” and an average target price of $42.00.

CervoMed Trading Down 1.6 %

NASDAQ:CRVO opened at $1.90 on Friday. CervoMed has a one year low of $1.81 and a one year high of $26.38. The stock has a 50-day simple moving average of $11.04 and a 200 day simple moving average of $14.53.

CervoMed (NASDAQ:CRVO) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.14). The company had revenue of $1.94 million for the quarter, compared to analyst estimates of $1.75 million. CervoMed had a negative return on equity of 44.11% and a negative net margin of 118.68%.

Institutional Investors Weigh In On CervoMed

A number of institutional investors and hedge funds have recently bought and sold shares of CRVO. Fred Alger Management LLC bought a new stake in shares of CervoMed during the 2nd quarter worth $60,000. FMR LLC purchased a new stake in shares of CervoMed during the third quarter valued at $56,000. Rhumbline Advisers acquired a new position in shares of CervoMed in the 2nd quarter valued at $96,000. Barclays PLC increased its stake in CervoMed by 323.6% in the 3rd quarter. Barclays PLC now owns 7,748 shares of the company’s stock worth $113,000 after purchasing an additional 5,919 shares in the last quarter. Finally, Bank of New York Mellon Corp acquired a new stake in CervoMed during the 2nd quarter worth about $236,000. 25.15% of the stock is owned by institutional investors and hedge funds.

CervoMed Company Profile

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.